These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9802389)

  • 41. Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist.
    Schneider E; Keller M; Brennauer A; Hoefelschweiger BK; Gross D; Wolfbeis OS; Bernhardt G; Buschauer A
    Chembiochem; 2007 Nov; 8(16):1981-8. PubMed ID: 17876753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BIBP 3226 inhibition of nicotinic receptor mediated chromaffin cell secretion.
    Zhang P; Zheng J; Hexum TD
    Eur J Pharmacol; 1998 Dec; 362(2-3):121-5. PubMed ID: 9874161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
    Keller M; Erdmann D; Pop N; Pluym N; Teng S; Bernhardt G; Buschauer A
    Bioorg Med Chem; 2011 May; 19(9):2859-78. PubMed ID: 21493077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices.
    King PJ; Widdowson PS; Doods HN; Williams G
    J Neurochem; 1999 Aug; 73(2):641-6. PubMed ID: 10428060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-affinity relationships of C-terminal cyclic analogue of neuropeptide Y for the Y1-receptor.
    Takebayashi Y; Koga H; Togami J; Kurihara H; Furuya T; Tanaka A; Murase K
    Chem Pharm Bull (Tokyo); 2000 Dec; 48(12):1925-9. PubMed ID: 11145146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropeptide Y-mediated constriction and dilation in rat middle cerebral arteries.
    You J; Edvinsson L; Bryan RM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):77-84. PubMed ID: 11149671
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intra-amygdala infusion of the NPY Y1 receptor antagonist BIBP 3226 attenuates operant ethanol self-administration.
    Schroeder JP; Olive F; Koenig H; Hodge CW
    Alcohol Clin Exp Res; 2003 Dec; 27(12):1884-91. PubMed ID: 14691375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY.
    Balasubramaniam A; Ujhelyi M; Borchers M; Huang Y; Zhai W; Zhou Y; Johnson M; Sheriff S; Fischer JE
    J Med Chem; 1996 Mar; 39(5):1142-7. PubMed ID: 8676351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuropeptide Y inhibits capsaicin-sensitive nociceptors via a Y1-receptor-mediated mechanism.
    Gibbs J; Flores CM; Hargreaves KM
    Neuroscience; 2004; 125(3):703-9. PubMed ID: 15099684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Actions of neuropeptide Y on the rat adrenal cortex.
    Renshaw D; Thomson LM; Carroll M; Kapas S; Hinson JP
    Endocrinology; 2000 Jan; 141(1):169-73. PubMed ID: 10614636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal and cardiovascular role of the neuropeptide Y Y1 receptor in ischaemic heart failure rats.
    Zhao XH; Sun XY; Bergdahl A; Edvinsson L; Hedner T
    J Pharm Pharmacol; 1999 Nov; 51(11):1257-65. PubMed ID: 10632083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations.
    Beck-Sickinger AG; Wieland HA; Wittneben H; Willim KD; Rudolf K; Jung G
    Eur J Biochem; 1994 Nov; 225(3):947-58. PubMed ID: 7957231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuropeptide Y suppresses epileptiform activity in rat frontal cortex and hippocampus in vitro via different NPY receptor subtypes.
    Bijak M
    Neurosci Lett; 1999 Jun; 268(3):115-8. PubMed ID: 10406018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vascular neuropeptide Y Y1-receptors in the rat kidney: vasoconstrictor effects and expression of Y1-receptor mRNA.
    Modin A; Malmström RE; Meister B
    Neuropeptides; 1999 Aug; 33(4):253-9. PubMed ID: 10657500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dissociation of potentiation of Leu31 Pro34 neuropeptide Y on adrenergic and purinergic transmission in isolated canine splenic artery.
    Yang XP; Chiba S
    Jpn J Pharmacol; 2000 Jul; 83(3):197-205. PubMed ID: 10952068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contractile effects of neuropeptide Y in human subcutaneous resistance arteries are mediated by Y1 receptors.
    Nilsson T; Erlinge D; Cantera L; Edvinsson L
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):764-8. PubMed ID: 8961073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
    Gehlert DR; Schober DA; Morin M; Berglund MM
    Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 1,3-Disubstituted benzazepines as neuropeptide Y Y1 receptor antagonists.
    Murakami Y; Hagishita S; Okada T; Kii M; Hashizume H; Yagami T; Fujimoto M
    Bioorg Med Chem; 1999 Aug; 7(8):1703-14. PubMed ID: 10482462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.
    Pluym N; Baumeister P; Keller M; Bernhardt G; Buschauer A
    ChemMedChem; 2013 Apr; 8(4):587-93. PubMed ID: 23361914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distribution of [Leu31,Pro34]NPY-sensitive, BIBP3226-insensitive [125I]PYY(3-36) binding sites in rat brain: possible relationship to Y5 NPY receptors.
    Widdowson PS; Buckingham R; Williams G
    Brain Res; 1997 Dec; 778(1):242-50. PubMed ID: 9462897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.